2 years ago

BDD Pharma Secures £2 Million to Accelerate Drug Development

  • BDD Pharma, a UK-based integrated drug formulation and clinical trials company, has raised £2 million in funding

  • The round was led by existing investors including angel syndicate Archangels, Scottish Enterprise, and new investor British Business Bank

  • BDD Pharma intends to use the funds to accelerate business expansion

  • The company's patented oral drug delivery technology, OralogiK™, enables the timed release of active pharmaceutical ingredients tailored to specific modified-release needs, including sustained, delayed, multiple pulse, and site-targeted release.

      • ProblemHealthcare

      "Pharmaceutical companies need to develop new drugs and get them to market quickly and efficiently. However, this process can be expensive and time-consuming. There is a need for a company that can provide a comprehensive suite of services to help pharmaceutical companies develop their products more efficiently."

      Solution

      "BDD Pharma provides a comprehensive suite of services to help pharmaceutical companies develop their products more efficiently. This includes formulation development, GMP manufacture, clinical trial services, and oral drug delivery technology. BDD Pharma’s patented oral drug delivery technology, OralogiK™, enables the timed release of active pharmaceutical ingredients tailored to specific modified-release needs. This technology supports the development of novel complex formulations and life cycle management opportunities. BDD Pharma’s services can help pharmaceutical companies reduce the time it takes to get their products to market and make the process more cost-effective."

      Covered on